Innovative
Biopharmaceutical Company

Based on Mitochondria

Who We Are

PAEAN Biotechnology, a pioneer in mitochondria-based therapeutics, is the first company to develop mitochondria as biopharmaceutical agents to treat diseases. Using our first-in-class proprietary technology of isolating, storing, and modifying mitochondria, we developed a revolutionary treatment to address rare diseases and cancer.

Mission

PAEAN Biotechnology strives to develop revolutionary first-in-class medicinal products through a proprietary platform based on the unique characteristics of mitochondria. We have developed three platforms of MitoTransfer.

Mitochondrial Therapeutics

Read more >>

Mitochondrial Cell Therapeutics

Read more >>

Modified Mitochondria Complex

Read more >>

Milestone

Research Collaboration

Seoul National University Hospital



2018 - Now

Pre-series A Funding

Korea Investment Partners



KRW 1.5 B

Jun 2018

Series A Funding

Korea Investment Partners, Hana Ventures, Timefolio


KRW 6 B

Jun 2019

Bridge Funding

Korea Investment Partners, Hana Ventures, Timefolio


KRW 4.5 B

Jan 2021

Mitochondria GMP Facility



Jung-gu, Seoul

Jun 2021

PN-101 MFDS IND Approval

World-first allogeneic mitochondria as therapeutic agent

Jun 2021

Research Collaboration

MOU with Soonchunhyang University Medical Center and SIMS

Sep 2021

Press Highlights

미토콘드리아 치료제 세계 첫 임상… 면역세포 치료-항암제까지

Source: https://www.donga.com/news/It/article/all/20220423/113035474/1?ref=main

Read more >>
Apr 23, 2022

파이안바이오 “미토콘드리아 유럽 임상 위한 CMO 계약 논의”

Source: https://www.hankyung.com/it/article/202112071993i

Read more >>
Dec 07, 2021

[유망기업] 미토콘드리아로 세계 첫 임상 나선 파이안바이오테크놀로지

Source: https://www.hankyung.com/it/article/202110202008i

Read more >>
Oct 25, 2021